share_log

Shanghai Haohai Biological Technology (HKG:6826) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Shanghai Haohai Biological Technology (HKG:6826) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

上海浩海生物科技(HKG: 6826)公佈了可觀的收益,但還有其他一些因素需要注意
Simply Wall St ·  03/15 18:21

Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) just reported some strong earnings, and the market reacted accordingly with a healthy uplift in the share price. However, our analysis suggests that shareholders may be missing some factors that indicate the earnings result was not as good as it looked.

上海浩海生物技術有限公司(HKG: 6826)剛剛公佈了一些強勁的收益,市場做出了相應的反應,股價出現了健康的上漲。但是,我們的分析表明,股東可能遺漏了一些表明盈利業績不如預期的因素。

earnings-and-revenue-history
SEHK:6826 Earnings and Revenue History March 15th 2024
SEHK: 6826 2024 年 3 月 15 日的收益和收入記錄

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

To properly understand Shanghai Haohai Biological Technology's profit results, we need to consider the CN¥40m gain attributed to unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

爲了正確理解上海浩海生物科技的盈利業績,我們需要考慮不尋常項目帶來的4000萬元人民幣的收益。雖然獲得更高的利潤總是件好事,但來自不尋常物品的巨額捐款有時會抑制我們的熱情。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。考慮到這個名字,這並不奇怪。假設這些不尋常的項目在本年度不會再次出現,因此我們預計明年的利潤將疲軟(也就是說,在業務沒有增長的情況下)。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On Shanghai Haohai Biological Technology's Profit Performance

我們對上海浩海生物科技盈利表現的看法

Arguably, Shanghai Haohai Biological Technology's statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Shanghai Haohai Biological Technology's true underlying earnings power is actually less than its statutory profit. But on the bright side, its earnings per share have grown at an extremely impressive rate over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. While it's really important to consider how well a company's statutory earnings represent its true earnings power, it's also worth taking a look at what analysts are forecasting for the future. So feel free to check out our free graph representing analyst forecasts.

可以說,提高利潤的不尋常項目扭曲了上海浩海生物科技的法定收益。因此,在我們看來,上海浩海生物科技的真正潛在盈利能力實際上可能低於其法定利潤。但好的一面是,其每股收益在過去三年中以極其驚人的速度增長。本文的目標是評估我們在多大程度上可以依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。儘管考慮公司的法定收益如何代表其真正的盈利能力非常重要,但也值得一看分析師對未來的預測。因此,請隨時查看我們代表分析師預測的免費圖表。

This note has only looked at a single factor that sheds light on the nature of Shanghai Haohai Biological Technology's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

這份報告只研究了揭示上海浩海生物科技盈利性質的單一因素。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論